LEGN — Legend Biotech Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1801198 ·
Last close
$19.11
Market Cap
$3.72B
52W High
$37.50
52W Low
$16.24
ADV30
2,084,117
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 387,500,000 | 250,100,000 | 57,700,000 | 33,200,000 | 1,750,900,000 | 672,900,000 | 521,300,000 |
| Mar 2026 | 305,100,000 | 129,200,000 | -49,800,000 | -54,300,000 | 1,596,700,000 | 646,400,000 | 629,000,000 |
| Dec 2025 | 306,377,000 | 182,918,000 | -20,602,000 | -30,815,000 | 1,733,700,000 | 901,900,000 | 731,600,000 |
| Sep 2025 | 272,330,000 | 157,024,000 | -43,452,000 | -39,689,000 | 1,712,948,000 | 278,893,000 | 701,688,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,700,000
Investing CF
$285,000,000
Financing CF
$-2,100,000
CapEx
$-34,100,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,012,800,000
Inventory
$37,100,000
Receivables
$186,600,000
ST Investments
$188,200,000
EBIT TTM
$-214,731,000
Pretax Income TTM
$-236,570,000
Interest Exp TTM
$21,839,000
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,271,399,936
EBITDA
$-41,600,000
Free Cash Flow
$27,193,000
Enterprise Value
$2,925,462,784
Total Cash
$964,600,000
Total Debt
$278,200,000
Shares Out
194,488,413
Trailing EPS
$-0.50
Book Value
$6.35
ROE
-8.1%
ROA
-1.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,028,900,000 | -136,500,000 | -296,800,000 | 1,733,700,000 | 731,600,000 | 1,002,100,000 | -100,200,000 |
| Dec 2024 | 627,300,000 | -309,500,000 | -177,000,000 | 1,670,200,000 | 629,600,000 | 1,040,600,000 | -144,000,000 |
| Dec 2023 | 285,100,000 | -528,100,000 | -518,300,000 | 1,848,609,000 | 597,238,000 | 1,251,371,000 | -393,300,000 |
| Dec 2022 | 117,005,000 | -455,620,000 | -446,349,000 | 1,330,963,000 | 586,651,000 | 744,312,000 | -201,281,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.05
Max Pain — expiry 2027-01-15
max pain strike: $20.00 · spot: $18.53 · call oi: 2,692 · put oi: 1,151
Expected Move to 2027-01-15:
±$5.40
(29.13%) —
implied range
$13.13 –
$23.93
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.63B | $75.08 | — |
| OGN | Organon & Co. | $3.61B | $13.73 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.58B | $36.94 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.56B | $20.68 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.89B | $11.45 | — |
News headlines (Yahoo Finance, 1h cache)
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
2026-09-25 11:00 · Yahoo
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
2026-09-15 23:40 · Yahoo
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
2026-09-15 12:00 · Yahoo
Legend Naming Novartis Executive as CEO
2026-09-15 11:30 · Yahoo
Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?
2026-09-02 06:10 · Yahoo
Legend Biotech (LEGN) Stock May Be Undervalued Despite A 70% 3 Year Fall
2026-09-01 15:10 · Yahoo
The hidden scale-out problem behind CAR-T’s growth
2026-09-01 13:08 · Yahoo
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
2026-09-01 12:00 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-08-12 19:58 · Yahoo
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript
2026-08-12 00:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.